Il Consiglio medico-scientifico della Società svizzera SM (CMS) pubblica linee guida e dichiarazioni su vari argomenti di carattere medico. Queste pubblicazioni sono rivolte agli operatori sanitari e sono pubblicate nelle rispettive lingue.
Linee guida per i professionisti
Pubblicazioni del Consiglio medico-scientifico
Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland — A Structured Commentary, Update 2022
Abstract
Multiple sclerosis (MS), particularly relapsing MS (RMS), has become a treatable disease in recent decades, and immunotherapies are now able to influence long-term disease course. A wide range of disease-modifying drugs are available, which makes the choice of therapy in individual cases considerably more complex. Due to specific regulatory aspects (partly diverging approvals by Swissmedic compared to the European Medicines Agency (EMA), and an independent evaluation process for the Federal Office of Public Health (FOPH) specialities list (SL)), we issued a consensus recommendation regarding specific aspects of immunotherapy for MS in Switzerland in 2019. Here, we present revised recommendations with an update on newly approved drugs and new safety aspects, also in reference to the risk of COVID-19 infection and vaccination.
